NXV 01
Alternative Names: NXV-01; NXV-01cLatest Information Update: 16 Jun 2024
At a glance
- Originator neoX Biotech
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Apr 2024 Preclinical trials in Solid tumours in China (Parenteral)
- 05 Apr 2024 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 18 Jan 2024 Early research in Solid tumours in China (Parenteral), prior to January 2024 (neoX Biotech pipeline, January 2024)